A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Rami S. Komrokji, Sheng Wei, Adam W. Mailloux, Ling Zhang, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Sara Tinsley, Lisa Nardelli, Javier Pinilla‐Ibarz,

Clinical Lymphoma Myeloma & Leukemia · 2018 · 40 citations · 7 references

Concepts

References

7